The Impact of Infliximab Trough Level and Anti-Drug Antibody on Clinical Outcomes in Crohn's Disease Patients: A Cross-Sectional Study in Iraq
Introduction: Primary non-response and secondary loss of response, often mediated by the development of anti-drug antibodies (ADAs), limit treatment efficacy. Therapeutic drug monitoring (TDM) is gaining importance in optimizing infliximab therapy by correlating drug levels with clinical outcomes. This study aimed to i...